This may be a dream come true. A small team of Israeli scientists is telling the world they will have the first “complete cure” for cancer within a year, according to The Jerusalem Post. They also claim that their cure will be brief, cheap and effective and will have no or minimal side-effects.
“We believe we will offer in a year’s time a complete cure for cancer,” said Dan Aridor, chairman of the board of Accelerated Evolution Biotechnologies Ltd. (AEBi).
“Our cancer cure will be effective from day one, will last a duration of a few weeks and will have no or minimal side-effects at a much lower cost than most other treatments on the market,” Aridor said. “Our solution will be both generic and personal.”
Called MuTaTo (multi-target toxin), researchers said the drug is essentially “on the scale of a cancer antibiotic–a disruption technology of the highest order.”
This is certainly a potential game-changer in the world-wide fight against cancer and will use a combination of cancer-targeting peptides and a toxin that will specifically kill cancer cells.
A team of scientists won the Nobel Prize last year for their work on phage display in the directed evolution of new proteins – in particular, for the production of antibody therapeutics, The Jerusalem Post reported.
“AEBi is doing something similar but with peptides, compounds of two or more amino acids linked in a chain.” According to Morad, peptides have several advantages over antibodies, including that they are smaller, cheaper, and easier to produce and regulate.
Aridor said AEBi is in the process of writing patents on specific peptides, which will be a large bank of targeting toxin peptides wholly owned and hard to break.
The company has finished exploratory mice experiments, which “inhibited human cancer cell growth and had no effect at all on healthy mice cells, in addition to several in-vitro trials,” The Jerusalem Post reported.
Next, AEBi will begin a round of clinical trials which could be completed within a few years and would make the treatment available in specific cases.
“Our results are consistent and repeatable,” Aridor said.